Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships
Austin, Texas, United States, April 10th, 2026, FinanceWire LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to […]









